Intermittent doxercalciferol (1α-hydroxyvitamin d2) therapy for secondary hyperparathyroidism

American Journal of Kidney Diseases

Volumn 36, Issue 3, 2000, Pages 550-561

  Frazão, João M ^a,b,c,d,e,f   Elangovan, Loganathan ^a,b,c,d,e,f   Maung, Hla M ^a,b,c,d,e,f   Chesney, Russell W ^a,b,c,d,e,f   Acchiardo, Sergio R ^a,b,c,d,e,f   Bower, John D ^a,b,c,d,e,f   Kelley, Bobby J ^a,b,c,d,e,f   Rodriguez, Hector J ^a,b,c,d,e,f   Norris, Keith C ^a,b,c,d,e,f   Robertson, John A ^a,b,c,d,e,f   Levine, Barton S ^a,b,c,d,e,f   Goodman, William G ^a,b,c,d,e,f   Gentile, Dominick ^a,b,c,d,e,f   Mazess, Richard B ^a,b,c,d,e,f   Kyllo, Darlene M ^a,b,c,d,e,f   Douglass, Laura L ^a,b,c,d,e,f   Bishop, Charles W ^a,b,c,d,e,f   Coburn, Jack W ^a,b,c,d,e,f  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f BoneCare International Inc   (United States)

Author keywords

1 hydroxyvitamin D2 (1 D2); Doxercalciferol (1 D2); Hemodialysis (HD); Intact parathyroid hormone (iPT14); Placebo controlled; Renal failure; Renal osteodystrophy; Therapeutic trial; Vitamin D

Indexed keywords

DOXERCALCIFEROL; PLACEBO; 1 ALPHA HYDROXYERGOCALCIFEROL; 1 ALPHA-HYDROXYERGOCALCIFEROL; ALKALINE PHOSPHATASE; CALCIUM; ERGOCALCIFEROL; PARATHYROID HORMONE; PHOSPHORUS;

ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; HEMODIALYSIS; HORMONE INHIBITION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; ADULT; AGED; BLOOD; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ALKALINE PHOSPHATASE; CALCIUM; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS;

EID: 0033624518     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2000.16193     Document Type: Article

References (43)

1. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
2. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
3. Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism
4. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism
5. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
6. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
7. 2: A new look at an 'old' compound
8. 2 in hemodialysis patients with moderates to severe secondary hyperparathyroidism
9. 2 in suppressing 2°hyperparathyroidism in hemodialysis patients
10. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
11. The spectrum of bone disease in end-stage renal failure - An evolving disorder
12. Accumulation of a non (1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance of the interpretation of PTH values
13. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurement in uremic samples
14. Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure
15. 2 in mammals
16. 3 in New World primates: Influence on calcium absorptions
17. Hypervitaminosis D in the New World monkeys
18. Antirachitic activity of 1α-hydroxyergocalciferol and 1α-hydroxycholecalciferol in rats
19. 3 in the rat
20. 2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3 osteoblastic cells
21. 2 detectable in human serum
22. 2 made in the human hepatoma, Hep 3B
23. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy
24. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol
25. The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism
26. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients
27. Is intermittent oral calcitriol safe and effective in renal secondary hyperpara-thyroidism?
28. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients
29. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis
30. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intrave-nous calcitriol
31. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
32. 3 inhibits parathyroid cell proliferation in experimental uremia
33. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
34. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study
35. Association of hyperphosphatemia with haemodynamic disturbances in end-stage renal disease
36. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients
37. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure
38. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
39. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD
40. Hypovitaminosis D in medical inpatients
41. Is low plasma 25(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol
42. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism
43. 3 and low dialysate calcium